Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Clinical trial NCT03756298 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03756298
- Sponsor
- National Cancer Center, Korea
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-15
- Primary completion
- 2026-12-31
- Enrollment
- 284
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.